Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment

Yao An Shen, Chi Long Chen, Yi Hsuan Huang, Emily Elizabeth Evans, Chun Chia Cheng, Ya Jie Chuang, Cissy Zhang, Anne Le

研究成果: 雜誌貢獻回顧型文獻同行評審

9 引文 斯高帕斯(Scopus)

摘要

Targeting glutamine catabolism has been attracting more research attention on the development of successful cancer therapy. Catalytic enzymes such as glutaminase (GLS) in glutaminolysis, a series of biochemical reactions by which glutamine is converted to glutamate and then alpha-ketoglutarate, an intermediate of the tricarboxylic acid (TCA) cycle, can be targeted by small molecule inhibitors, some of which are undergoing early phase clinical trials and exhibiting promising safety profiles. However, resistance to glutaminolysis targeting treatments has been observed, necessitating the development of treatments to combat this resistance. One option is to use synergy drug combinations, which improve tumor chemotherapy's effectiveness and diminish drug resistance and side effects. This review will focus on studies involving the glutaminolysis pathway and diverse combination therapies with therapeutic implications.
原文英語
頁(從 - 到)64-81
頁數18
期刊Current Opinion in Chemical Biology
62
DOIs
出版狀態已發佈 - 6月 2021

ASJC Scopus subject areas

  • 分析化學
  • 生物化學

指紋

深入研究「Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment」主題。共同形成了獨特的指紋。

引用此